A stop-smoking mobile app that senses where and when you might be triggered to light up could help you quit, according to University of East Anglia research. Quit Sense is the world’s first Artificial Intelligence (AI) stop smoking app that detects when people are entering a location where they used to smoke. It then provides support to help manage people’s specific smoking triggers in that location. A study published today shows how the new app helped more smokers to quit than people who were only offered online NHS support. The research team hopes that by helping people manage trigger situations, the new app will help more smokers to quit. The work is published in Nicotine and Tobacco Research. Lead researcher Prof Felix Naughton, from UEA’s School of Health Sciences, said, “We know that quit attempts often fail because urges to smoke are triggered by spending time ...
More than 2.5 million cases of sexually transmitted infections were reported in 2021, jumping by 7% in one year, according to new data from the US Centers for Disease Control and Prevention. “The US STI epidemic shows no signs of slowing,” said Dr. Leandro Mena, director of the CDC’s Division of STD Prevention. Chlamydia accounted for more than half of the reported cases, with rates increasing about 4% in 2021. Cases of gonorrhea rose nearly 5%. Cases of syphilis surged 32% in one year, including an alarming rise in infections passed from pregnant mothers to babies developing in the womb. In 2021, congenital syphilis caused 220 stillbirths and infant deaths. “The most important thing to remember is that congenital syphilis is 100% preventable,” Mena said. “In many ways, it is the result of our failure to prevent syphilis among women of reproductive age and their partners.” ...
After decades under Johnson & Johnson, a massive plant that once cranked out over-the-counter mainstays like Pepcid and Imodium is poised to hit the market. The plant handover comes after last month’s news that Johnson & Johnson would cut 57 positions at the Lancaster County facility, as detailed in a local Worker Adjustment and Retraining Notification Act notice. High Properties acquired J&J’s Greenfield, Pennsylvania, consumer health facility for $14 million, local news outlet Lancaster Online first reported. Fierce Pharma has viewed a copy of the deed confirming the sale, which went through in late March. J&J and High Properties did not immediately respond to Fierce Pharma’s request for comment on the matter. Reference: https://deal.town/questex/041223-takeda-hit-with-another-pay-for-delay-lawsuit-after-layoff-warning-jandj-inks-14m-plant-sale-F34YGQUSL
U.S. neurologists are “cautiously optimistic” about using Eisai’s Leqembi in Alzheimer’s disease as concerns about safety and the need for the FDA’s full green light for the drug remain high barriers to uptake. That’s according to a new survey and report out by drug launch analyst Spherix Global Insights, which in March asked 73 neurologists working in the U.S. about their use and receptivity of Leqembi, which was partially approved by the FDA at the start of the year. Now launched, the drug finds itself at a strange junction. It still does not have a full FDA approval; that isn’t set to come until early July. While there is another new drug on the market for Alzheimer’s—namely Aduhelm, which Eisai helped create with Biogen—that drug is commercially dead in the water. The Centers for Medicare & Medicaid Services (CMS) refused to cover payments of Aduhelm, which was ...
April 11, 2023 By Jim Hammerand Leave a Comment FacebookTwitterLinkedIn分享 Burn patients wear the masks on their face to heal scars and prevent complications. “I almost prefer to have the mask on,” said patient Laura Weibel (pictured on the left). [Photo courtesy of Formlabs] 3D-printed masks are removing a traumatic part of treatment for children recovering from severe burns. At Romans Ferrari pediatric rehabilitation center in France, a child with facial burns previously would need to sit motionless for a plaster cast of their face to make a mask for treatment. The masks compress the skin to help scars heal without complications, but the heat from warm plaster bandages can make young burn victims uncomfortable — or worse. “It required the patients to be motionless for the duration of the plaster cast that lasts about half an hour, which can be difficult, especially for children, and could reactivate symptoms of post-traumatic stress ...
April 13, 2023 By Sean Whooley Leave a Comment FacebookTwitterLinkedIn分享 Rice University Ph.D. student Tyler Graf holds a microscope slide. It holds an array of more than 300 tiny biodegradable particles. These can be used for time-released drug delivery. (Photo by Brandon Martin/Rice University) Bioengineers at Rice University developed a new technology for delivering drugs in a time-releasing manner. Kevin McHugh, corresponding author of a study about the technology, believes this could make missing doses of medicines and vaccines a thing of the past. McHugh and the Rice team saw their work published online in Advanced Materials. According to McHugh and graduate student Tyler Graf, encapsulating medicine in microparticles that dissolve and release drugs over time isn’t new. However, they believe their method — using 21st century methods to develop next-level encapsulation technology —offers more versatility in medication delivery. “This is a huge problem in the treatment of chronic disease,” McHugh said in a post ...
A three-judge panel decided mifepristone’s FDA approval shouldn’t be revoked, but its decision could still make the drug much harder to obtain. An appellate court has blocked a ruling that would have suspended the approval of a decades-old abortion pill, but decided the medicine should only stay on the market with strict limitations. The 2-1 decision from the U.S. Court of Appeals for the 5th Circuit upholds the Food and Drug Administration’s 2000 approval of mifepristone, a medicine used in more than half of all U.S. abortions and to treat miscarriages. But the panel also unwound long-running efforts by the regulator to expand access to mifepristone in recent years. Since 2016, the FDA has enabled the drug to be used through ten weeks of gestation, instead of seven. The agency has also allowed the medication to be delivered by mail and prescribed through a teleheath visit, rather than ...
Chiesi Farmaceutici has completed the previously announced acquisition of global, commercial-stage biopharmaceutical company Amryt Pharma. The definitive agreement between the companies was initially signed in January this year. The total deal value at close is nearly $1.2bn in upfront consideration and contingent value rights (CVRs) representing an additional potential consideration of around $225m. Chiesi Global Rare Diseases head Giacomo Chiesi said: “Amryt has unique and clinically differentiated products and additional promising drugs in its pipeline, and, as a benefit corporation certified B Corp, Chiesi has a patient-centric and sustainable model in place to make these treatments available to even more patients who need them.” With this acquisition, Chiesi will be able to expand patient access to approved treatments and also advance efforts for the development of new treatments for individuals with rare diseases. Chiesi Group CEO Giuseppe Accogli said: “This acquisition reflects Chiesi Group’s commitment towards patients. ...
In the 1835 Hans Christian Andersen fairy tale “The Princess and the Pea,” a princess is deemed authentic because of her sensitivity to a pea placed under 20 mattresses on her bed. New research from the McKelvey School of Engineering at Washington University in St. Louis has found that like the fabled princess, cancer cells can sense a layer of cells beneath the top collagen layer on which they normally travel, while normal cells cannot. Amit Pathak, an associate professor of mechanical engineering and materials science, and Christopher Walter, a postdoctoral research associate in Pathak’s lab, found that cancer cells have what they term “depth mechanosensing,” or the ability to sense the properties of the distant environments underneath their immediate extracellular matrix. This could mean that the mechanical properties of extracellular matrices located away from the cells could regulate cell migration. Results of their research were published online in Cell Reports on April 5. Pathak ...
A technique that identifies the build-up of abnormal protein deposits linked to Parkinson’s disease could aid in early detection and play a key role in the disease’s clinical diagnosis and characterization, according to research published in The Lancet Neurology journal. Findings from the study confirm that the technique—known as α-synuclein seed amplification assay (αSyn-SAA)—can accurately detect people with the neurodegenerative disease and suggest it can identify at-risk individuals and those with early, non-motor symptoms prior to diagnosis. The presence of misfolded α-synuclein protein aggregates in the brain is the pathological hallmark of Parkinson’s disease. Co-lead author Professor Andrew Siderowf, of the University of Pennsylvania Perelman School of Medicine (U.S.) and Parkinson Progression Marker Initiative (PPMI) investigator, says, “Recognizing heterogeneity in underlying pathology among patients with Parkinson’s disease has been a major challenge. Identifying an effective biomarker for Parkinson’s disease pathology could have profound implications for the way we treat the condition, potentially ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.